Royalty Pharma plc and Royalty Pharma Finance Corporation, 66214 [2022-23788]

Download as PDF 66214 Federal Register / Vol. 87, No. 211 / Wednesday, November 2, 2022 / Notices 2022. No more than three minutes shall be allotted to each speaker. The time allotted to each speaker will be determined after registration closes. Registration for the public comment period, either in person or via teleconference, will end on November 8 at noon ET. Participation in the public comment period is governed by 39 CFR 232.1(n). CONTACT PERSON FOR MORE INFORMATION: Michael J. Elston, Secretary of the Board of Governors, U.S. Postal Service, 475 L’Enfant Plaza SW, Washington, DC 20260–1000. Telephone: (202) 268– 4800. Michael J. Elston, Secretary. [FR Doc. 2022–23895 Filed 10–31–22; 11:15 am] BILLING CODE 7710–12–P POSTAL SERVICE Product Change—Priority Mail Express, Priority Mail, First-Class Package Service, and Parcel Select Service Negotiated Service Agreement AGENCY: ACTION: Postal ServiceTM. Notice. The Postal Service gives notice of filing a request with the Postal Regulatory Commission to add a domestic shipping services contract to the list of Negotiated Service Agreements in the Mail Classification Schedule’s Competitive Products List. SUMMARY: Date of required notice: November 2, 2022. DATES: FOR FURTHER INFORMATION CONTACT: Sean Robinson, 202–268–8405. The United States Postal Service® hereby gives notice that, pursuant to 39 U.S.C. 3642 and 3632(b)(3), on October 26, 2022, it filed with the Postal Regulatory Commission a USPS Request to Add Priority Mail Express, Priority Mail, First-Class Package Service, and Parcel Select Service Contract 74 to Competitive Product List. Documents are available at www.prc.gov, Docket Nos. MC2023–27, CP2023–26. khammond on DSKJM1Z7X2PROD with NOTICES SUPPLEMENTARY INFORMATION: Sarah Sullivan, Attorney, Ethics & Legal Compliance. [FR Doc. 2022–23851 Filed 11–1–22; 8:45 am] BILLING CODE 7710–12–P VerDate Sep<11>2014 16:38 Nov 01, 2022 Jkt 259001 SECURITIES AND EXCHANGE COMMISSION [Investment Company Act Release No. 34741; File No. 812–15386] Royalty Pharma plc and Royalty Pharma Finance Corporation October 27, 2022. Securities and Exchange Commission (‘‘Commission’’ or ‘‘SEC’’). ACTION: Notice. AGENCY: Notice of an application under section 6(c) of the Investment Company Act of 1940 (‘‘Act’’) for an exemption from all provisions of the Act. SUMMARY OF APPLICATION: Applicants request an order that would permit Royalty Pharma Finance Corporation (‘‘FinCo’’) to issue and sell commercial paper, preferred stock and other debt securities to finance the operations of Royalty Pharma plc (‘‘RP’’) and its subsidiaries. Applicants state that FinCo would qualify for the exemption provided by rule 3a–5 under the Act but for the facts that: (i) FinCo may finance various subsidiaries of RP that are not ‘‘companies controlled by’’ RP within the meaning of rule 3a–5 due to their reliance on sections 3(c)(5) or 3(c)(6) of the Act, (ii) FinCo is a direct subsidiary of Royalty Pharma Holdings Ltd., a wholly-owned subsidiary of RP, which would not be a ‘‘company controlled by the parent company’’ within the meaning of rule 3a–5 to the extent it relies on section 3(c)(6) of the Act, and (iii) FinCo’s ‘‘parent company’’ for purposes of rule 3a–5 would be RP, which would not be a ‘‘parent company’’ within the meaning of rule 3a–5 to the extent it relies on section 3(c)(6) of the Act. APPLICANTS: Royalty Pharma plc and Royalty Pharma Finance Corporation. FILING DATE: The application was filed on September 20, 2022. HEARING OR NOTIFICATION OF HEARING: An order granting the requested relief will be issued unless the Commission orders a hearing. Interested persons may request a hearing on any application by emailing the SEC’s Secretary at Secretarys-Office@sec.gov and serving the Applicants with a copy of the request by email, if an email address is listed for the relevant Applicant below, or personally or by mail, if a physical address is listed for the relevant Applicant below. Hearing requests should be received by the Commission by 5:30 p.m. on November 21, 2022, and should be accompanied by proof of service on applicants, in the form of an affidavit or, for lawyers, a certificate of service. Pursuant to rule 0–5 under the PO 00000 Frm 00088 Fmt 4703 Sfmt 4703 Act, hearing requests should state the nature of the writer’s interest, any facts bearing upon the desirability of a hearing on the matter, the reason for the request, and the issues contested. Persons who wish to be notified of a hearing may request notification by emailing the Commission’s Secretary at Secretarys-Office@sec.gov. ADDRESSES: The Commission: Secretarys-Office@sec.gov. Applicants: Gregory S. Rowland, gregory.rowland@ davispolk.com. FOR FURTHER INFORMATION CONTACT: Steven I. Amchan, Senior Counsel, or Lisa Reid Ragen, Branch Chief, at (202) 551–6825 (Division of Investment Management, Chief Counsel’s Office). SUPPLEMENTARY INFORMATION: For Applicants’ representations, legal analysis, and conditions, please refer to Applicants’ application, dated September 20, 2022, which may be obtained via the Commission’s website by searching for the file number at the top of this document, or for an Applicant using the Company name search field, on the SEC’s EDGAR system. The SEC’s EDGAR system may be searched at, at https://www.sec.gov/ edgar/searchedgar/legacy/ companysearch.html. You may also call the SEC’s Public Reference Room at (202) 551–8090. For the Commission, by the Division of Investment Management, under delegated authority. J. Matthew DeLesDernier, Deputy Secretary. [FR Doc. 2022–23788 Filed 11–1–22; 8:45 am] BILLING CODE 8011–01–P SECURITIES AND EXCHANGE COMMISSION [Release No. 34–96164; File No. SR–MIAX– 2022–39] Self-Regulatory Organizations: Notice of Filing and Immediate Effectiveness of a Proposed Rule Change by Miami International Securities Exchange, LLC To Amend Exchange Rule 1801, Definitions and Rule 1809, Terms of Index Options Contracts To Remove References to BRIXX Indexes October 27, 2022. Pursuant to the provisions of Section 19(b)(1) of the Securities Exchange Act of 1934 (‘‘Act’’) 1 and Rule 19b–4 thereunder,2 notice is hereby given that on October 24, 2022, Miami International Securities Exchange, LLC (‘‘MIAX Options’’ or the ‘‘Exchange’’) 1 15 2 17 U.S.C. 78s(b)(1). CFR 240.19b–4. E:\FR\FM\02NON1.SGM 02NON1

Agencies

[Federal Register Volume 87, Number 211 (Wednesday, November 2, 2022)]
[Notices]
[Page 66214]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-23788]


=======================================================================
-----------------------------------------------------------------------

SECURITIES AND EXCHANGE COMMISSION

[Investment Company Act Release No. 34741; File No. 812-15386]


Royalty Pharma plc and Royalty Pharma Finance Corporation

October 27, 2022.
AGENCY: Securities and Exchange Commission (``Commission'' or ``SEC'').

ACTION: Notice.

-----------------------------------------------------------------------

    Notice of an application under section 6(c) of the Investment 
Company Act of 1940 (``Act'') for an exemption from all provisions of 
the Act.

Summary of Application:  Applicants request an order that would permit 
Royalty Pharma Finance Corporation (``FinCo'') to issue and sell 
commercial paper, preferred stock and other debt securities to finance 
the operations of Royalty Pharma plc (``RP'') and its subsidiaries. 
Applicants state that FinCo would qualify for the exemption provided by 
rule 3a-5 under the Act but for the facts that: (i) FinCo may finance 
various subsidiaries of RP that are not ``companies controlled by'' RP 
within the meaning of rule 3a-5 due to their reliance on sections 
3(c)(5) or 3(c)(6) of the Act, (ii) FinCo is a direct subsidiary of 
Royalty Pharma Holdings Ltd., a wholly-owned subsidiary of RP, which 
would not be a ``company controlled by the parent company'' within the 
meaning of rule 3a-5 to the extent it relies on section 3(c)(6) of the 
Act, and (iii) FinCo's ``parent company'' for purposes of rule 3a-5 
would be RP, which would not be a ``parent company'' within the meaning 
of rule 3a-5 to the extent it relies on section 3(c)(6) of the Act.

Applicants:  Royalty Pharma plc and Royalty Pharma Finance Corporation.

Filing Date:  The application was filed on September 20, 2022.

Hearing or Notification of Hearing:  An order granting the requested 
relief will be issued unless the Commission orders a hearing. 
Interested persons may request a hearing on any application by emailing 
the SEC's Secretary at [email protected] and serving the 
Applicants with a copy of the request by email, if an email address is 
listed for the relevant Applicant below, or personally or by mail, if a 
physical address is listed for the relevant Applicant below. Hearing 
requests should be received by the Commission by 5:30 p.m. on November 
21, 2022, and should be accompanied by proof of service on applicants, 
in the form of an affidavit or, for lawyers, a certificate of service. 
Pursuant to rule 0-5 under the Act, hearing requests should state the 
nature of the writer's interest, any facts bearing upon the 
desirability of a hearing on the matter, the reason for the request, 
and the issues contested. Persons who wish to be notified of a hearing 
may request notification by emailing the Commission's Secretary at 
[email protected].

ADDRESSES: The Commission: [email protected]. Applicants: 
Gregory S. Rowland, [email protected].

FOR FURTHER INFORMATION CONTACT: Steven I. Amchan, Senior Counsel, or 
Lisa Reid Ragen, Branch Chief, at (202) 551-6825 (Division of 
Investment Management, Chief Counsel's Office).

SUPPLEMENTARY INFORMATION: For Applicants' representations, legal 
analysis, and conditions, please refer to Applicants' application, 
dated September 20, 2022, which may be obtained via the Commission's 
website by searching for the file number at the top of this document, 
or for an Applicant using the Company name search field, on the SEC's 
EDGAR system. The SEC's EDGAR system may be searched at, at https://www.sec.gov/edgar/searchedgar/legacy/companysearch.html. You may also 
call the SEC's Public Reference Room at (202) 551-8090.

    For the Commission, by the Division of Investment Management, 
under delegated authority.
J. Matthew DeLesDernier,
Deputy Secretary.
[FR Doc. 2022-23788 Filed 11-1-22; 8:45 am]
BILLING CODE 8011-01-P


This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.